z-logo
open-access-imgOpen Access
In Vitro Efficacies and Resistance Profiles of Rifampin-Based Combination Regimens for Biofilm-Embedded Methicillin-Resistant Staphylococcus aureus
Author(s) -
Hung-Jen Tang,
Chi-Chung Chen,
Kuo-Chen Cheng,
Kuan-Ying Wu,
Yi-Chung Lin,
Chun-Cheng Zhang,
TzuChieh Weng,
WenLiang Yu,
YuHsin Chiu,
Han Siong Toh,
Shyh-Ren Chiang,
Bo Su,
WenChien Ko,
Yin-Ching Chuang
Publication year - 2013
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01236-13
Subject(s) - tigecycline , fusidic acid , linezolid , fosfomycin , microbiology and biotechnology , daptomycin , teicoplanin , minocycline , biofilm , methicillin resistant staphylococcus aureus , staphylococcus aureus , vancomycin , antibiotics , biology , medicine , bacteria , genetics
To compare thein vitro antibacterial efficacies and resistance profiles of rifampin-based combinations against methicillin-resistantStaphylococcus aureus (MRSA) in a biofilm model, the antibacterial activities of vancomycin, teicoplanin, daptomycin, minocycline, linezolid, fusidic acid, fosfomycin, and tigecycline alone or in combination with rifampin against biofilm-embedded MRSA were measured. The rifampin-resistant mutation frequencies were evaluated. Of the rifampin-based combinations, rifampin enhances the antibacterial activities of and even synergizes with fusidic acid, tigecycline, and, to a lesser extent, linezolid, fosfomycin, and minocycline against biofilm-embedded MRSA. Such combinations with weaker rifampin resistance induction activities may provide a therapeutic advantage in MRSA biofilm-related infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom